+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Clinical Oncology Next Generation Sequencing Global Market Report 2021: COVID-19 Growth and Change to 2030

  • ID: 5315005
  • Report
  • April 2021
  • Region: Global
  • The Business Research Company

FEATURED COMPANIES

  • Agilent Technologies
  • Caris Life Sciences
  • Exosome Diagnostics
  • Genomatix Software
  • Life Technologies
  • Pacific Bioscience
  • MORE
Clinical Oncology Next Generation Sequencing Global Market Report 2021: COVID-19 Growth And Change To 2030 provides the strategists, marketers and senior management with the critical information they need to assess the global clinical oncology next generation sequencing market.

This report focuses on clinical oncology next generation sequencing market which is experiencing strong growth. The report gives a guide to the clinical oncology next generation sequencing market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.
Description:

Where is the largest and fastest growing market for the clinical oncology next generation sequencing? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Clinical Oncology Next Generation Sequencing market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider clinical oncology next generation sequencing market, and compares it with other markets.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The clinical oncology next generation sequencing market section of the report gives context. It compares the clinical oncology next generation sequencing market with other segments of the clinical oncology next generation sequencing market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, clinical oncology next generation sequencing indicatoScope
Markets Covered:
1) By Technology: Ion Semiconductor Sequencing; Pyro-Sequencing; Synthesis Sequencing; Real Time Sequencing; Ligation Sequencing; Reversible Dye Termination Sequencing; Nano-Pore Sequencing
2) By Application: Screening; Companion Diagnostics; Other Diagnostics3) By End User: Hospital Laboratories; Clinical Research Organizations; Diagnostic laboratories

Companies Mentioned: Thermo Fisher Scientific(Qiagen); Oxford Nanopore Technologies; QIAGEN; Myriad Genetics; Illumina

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Agilent Technologies
  • Caris Life Sciences
  • Exosome Diagnostics
  • Genomatix Software
  • Life Technologies
  • Pacific Bioscience
  • MORE
1. Executive Summary

2. Clinical Oncology Next Generation Sequencing Market Characteristics

3. Clinical Oncology Next Generation Sequencing Market Trends And Strategies

4. Impact Of COVID-19 On Clinical Oncology Next Generation Sequencing

5. Clinical Oncology Next Generation Sequencing Market Size And Growth
5.1. Global Clinical Oncology Next Generation Sequencing Historic Market, 2015-2020, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Clinical Oncology Next Generation Sequencing Forecast Market, 2020-2025F, 2030F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market

6. Clinical Oncology Next Generation Sequencing Market Segmentation
6.1. Global Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Ion Semiconductor Sequencing
  • Pyro-Sequencing
  • Synthesis Sequencing
  • Real Time Sequencing
  • Ligation Sequencing
  • Reversible Dye Termination Sequencing
  • Nano-Pore Sequencing
6.2. Global Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Screening
  • Companion Diagnostics
  • Other Diagnostics
6.3. Global Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Hospital Laboratories
  • Clinical Research Organizations
  • Diagnostic laboratories
7. Clinical Oncology Next Generation Sequencing Market Regional And Country Analysis
7.1. Global Clinical Oncology Next Generation Sequencing Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7.2. Global Clinical Oncology Next Generation Sequencing Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

8. Asia-Pacific Clinical Oncology Next Generation Sequencing Market
8.1. Asia-Pacific Clinical Oncology Next Generation Sequencing Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
8.3. Asia-Pacific Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

9. China Clinical Oncology Next Generation Sequencing Market
9.1. China Clinical Oncology Next Generation Sequencing Market Overview
9.2. China Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion
9.3. China Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion

10. India Clinical Oncology Next Generation Sequencing Market
10.1. India Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
10.2. India Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

11. Japan Clinical Oncology Next Generation Sequencing Market
11.1. Japan Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11.2. Japan Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

12. Australia Clinical Oncology Next Generation Sequencing Market
12.1. Australia Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
12.2. Australia Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

13. Indonesia Clinical Oncology Next Generation Sequencing Market
13.1. Indonesia Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
13.2. Indonesia Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

14. South Korea Clinical Oncology Next Generation Sequencing Market
14.1. South Korea Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
14.2. South Korea Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

15. Western Europe Clinical Oncology Next Generation Sequencing Market
15.1. Western Europe Clinical Oncology Next Generation Sequencing Market Overview
15.2. Western Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
15.3. Western Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

16. UK Clinical Oncology Next Generation Sequencing Market
16.1. UK Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
16.2. UK Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

17. Germany Clinical Oncology Next Generation Sequencing Market
17.1. Germany Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
17.2. Germany Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

18. France Clinical Oncology Next Generation Sequencing Market
18.1. France Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
18.2. France Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

19. Eastern Europe Clinical Oncology Next Generation Sequencing Market
19.1. Eastern Europe Clinical Oncology Next Generation Sequencing Market Overview
19.2. Eastern Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
19.3. Eastern Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

20. Russia Clinical Oncology Next Generation Sequencing Market
20.1. Russia Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
20.2. Russia Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

21. North America Clinical Oncology Next Generation Sequencing Market
21.1. North America Clinical Oncology Next Generation Sequencing Market Overview
21.2. North America Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
21.3. North America Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

22. USA Clinical Oncology Next Generation Sequencing Market
22.1. USA Clinical Oncology Next Generation Sequencing Market Overview
22.2. USA Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
22.3. USA Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

23. South America Clinical Oncology Next Generation Sequencing Market
23.1. South America Clinical Oncology Next Generation Sequencing Market Overview
23.2. South America Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
23.3. South America Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

24. Brazil Clinical Oncology Next Generation Sequencing Market
24.1. Brazil Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
24.2. Brazil Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

25. Middle East Clinical Oncology Next Generation Sequencing Market
25.1. Middle East Clinical Oncology Next Generation Sequencing Market Overview
25.2. Middle East Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
25.3. Middle East Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

26. Africa Clinical Oncology Next Generation Sequencing Market
26.1. Africa Clinical Oncology Next Generation Sequencing Market Overview
26.2. Africa Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
26.3. Africa Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

27. Clinical Oncology Next Generation Sequencing Market Competitive Landscape And Company Profiles
27.1. Clinical Oncology Next Generation Sequencing Market Competitive Landscape
27.2. Clinical Oncology Next Generation Sequencing Market Company Profiles
27.2.1. Thermo Fisher Scientific(Qiagen)
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. Oxford Nanopore Technologies
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. QIAGEN
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. Myriad Genetics
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. Illumina
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance

28. Key Mergers And Acquisitions In The Clinical Oncology Next Generation Sequencing Market

29. Clinical Oncology Next Generation Sequencing Market Future Outlook and Potential Analysis

30. Appendix
30.1. Abbreviations
30.2. Currencies
30.3. Research Inquiries
30.4. The Publisher
30.5. Copyright And Disclaimer
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Agilent Technologies
  • Caris Life Sciences
  • Exosome Diagnostics
  • Genomatix Software
  • Life Technologies
  • Pacific Bioscience
  • MORE
Major players in the clinical oncology next generation sequencing market are Thermo Fisher Scientific (Qiagen), Oxford Nanopore Technologies, QIAGEN, Myriad Genetics, Illumina, F. Hoffmann-La Roche, Perkin Elmer, Agilent Technologies, Pacific Bioscience, and Caris Life Sciences.

The global clinical oncology next generation sequencing market is expected to grow from $0.44 billion in 2020 to $0.56 billion in 2021 at a compound annual growth rate (CAGR) of 27.3%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $1.05 billion in 2025 at a CAGR of 17%.

The clinical oncology next generation sequencing market consists of sales of devices and equipment used in clinical oncology next generation sequencing and related services by entities (organizations, sole traders and partnerships) that manufacture clinical oncology next generation sequencing equipment. Next generation sequencing is a process used to determine the sequence of nucleotides in a section of DNA and is used for oncology research. Only goods and services traded between entities or sold to end consumers are included.

The clinical oncology next generation sequencing market covered in this report is segmented by technology into ion semiconductor sequencing, pyro-sequencing, synthesis sequencing, real time sequencing, ligation sequencing, reversible dye termination sequencing, nano-pore sequencing. It is also segmented by application into screening, companion diagnostics, other diagnostics and by end user into hospital laboratories, clinical research organizations, diagnostic laboratories.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

High costs associated with the clinical oncology next generation sequencing is a major issue faced by patients across the globe. The pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In low-income countries, the lack of cost-effective therapies for cancer has influenced the health conditions of the population and has led to a low average life expectancy. According to an article published in July 2019 by Genetics in Medicine, the genome sequencing costs per cancer case is around £6,841, and costs per rare disease are around £7,050, and this cost is due to consumables that are the most expensive components in the sequencing process, and the equipment cost for rare cancer disease is higher when compared with normal cancer equipment, thus restraining the growth of the market.

In August 2019, Agilent Technologies acquired BioTek Instruments for $1.2 billion. The acquisition is expected to grow the presence and expertise of Agilent in cell analysis and strengthens the position of Agilent in the large and growing immune-oncology and immunotherapy areas. BioTek Instruments is a Vermont-based company that sells scientific instruments and associated software.

The rise in the number of cancer cases across the globe is likely to contribute to the growth of the clinical oncology next generation sequencing market during the forecast period. According to the American Cancer Society, there were 1.7 million new cases and 0.6 million cancer deaths in 2019 in the USA. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all the new cancer cases. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for clinical oncology next generation sequencing market.

Companies in the clinical oncology next generation sequencing are increasingly investing in automation of workflow to increase precision and reduce the sample to sample variability. For instance, Agilent automation solutions have developed an automation system that allows increasing the number of reactions that can perform in parallel, and reducing the amount of sample processing time, and increasing the number of samples which can be processed while reducing the variability amount from sample to sample. Companies such as Sophia Genetics are also investing in data-driven medicine that looks into automating DNA sequencing to better diagnose and treat patients.

The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Note: Product cover images may vary from those shown
  • Thermo Fisher Scientific(Qiagen)
  • Oxford Nanopore Technologies
  • QIAGEN
  • Myriad Genetics
  • Illumina
  • F. Hoffmann-La Roche
  • Perkin Elmer
  • Agilent Technologies
  • Pacific Bioscience
  • Caris Life Sciences
  • Paradigm Diagnostics
  • GATC Biotech
  • Macrogen
  • Life Technologies
  • DNASTAR
  • Exosome Diagnostics
  • Biomatters
  • Partek
  • Foundation Medicine
  • BD
  • Takara Bio
  • Creative Biolabs
  • Mogene
  • Knome
  • Genomatix Software
  • CLC Bio
  • GnuBIO
  • Bio-Rad Laboratories
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll